Skip to main content
Premium Trial:

Request an Annual Quote

SeekIn Receives CE-IVD Mark for Cancer Recurrence Monitoring Test

NEW YORK – Liquid biopsy firm SeekIn said Monday that it has received a CE mark for its cancer recurrence monitoring test, SeekInCure, and is preparing to launch assay kits in the European Union and other countries that recognize the designation.

The Shenzhen, China-based firm has brought several other assays through this approval process over the last year, including SeekInClarity, a cancer treatment response monitoring test, and SeekInCare, a pan-cancer early detection kit.

SeekInCure is unlike many of the minimal residual disease assays on the market in the US. Instead of using upfront tumor tissue sequencing to design patient-specific mutation panels, the company uses a universal, artificial intelligence-derived algorithm that incorporates genomic, epigenomic, and proteomic signals.

"We have conducted a prospective study to evaluate the effectiveness of SeekInCure to detect MRD in patients with hepatocellular carcinoma (HCC), and this study has confirmed the excellent performance of SeekInCure in the detection of MRD and the prognostic value of MRD in HCC patients," SeekIn Founder and CEO Mao Mao said in a statement.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.